IFCC Scientific Symposia will be presented in the morning. Afternoon will be mostly dedicated to industry Educational Workshops.

TIME SCHEDULE: PROGRAMME WILL START AT 08.00 AM, US EASTERN TIME (CORRESPONDING TO: 14.00 ROME; 21.00 BEIJING)

All sessions will be recorded and fully available for registered people.
SCIENTIFIC PROGRAMME

PLENARY SESSION
Value & Impact of Clinical Laboratories in the COVID-19 Crisis

IFCC TASKFORCE ON COVID-19 – UPDATED GUIDELINES & FUTURE DIRECTIONS
Update from the IFCC COVID-19 taskforce on their most recent updated guidelines on laboratory biosafety and testing modalities, new initiatives and planned future directions

CLINICAL LABORATORY EXPERIENCE IN COVID-19 – GLOBAL PERSPECTIVES
Presentations from representatives of 6 regional federations across the world on their experience in COVID-19 testing and management

COVID-19 MANAGEMENT – FOCUS ON PUBLIC HEALTH AND REGULATION
Presentations from key public health and regulatory authorities (e.g. WHO, CDC, FDA) and panel discussion on COVID-19 management from a public health and regulatory perspective

TECHNOLOGICAL DEVELOPMENTS IN THE FIGHT AGAINST COVID-19
Scientific and industry presentations on in vitro diagnostics (latest advances in molecular diagnostic assays, serological and antigen assays, and biochemical/hematological testing of hospitalized patients), POCT new advanced therapeutics and vaccine development and planned implementation.

BREAKOUT SESSIONS (OCCUR CONCURRENTLY)
Invited experts from around the world in key areas of interest. Draft potential sessions include:
- Antigen and Molecular Testing: Supplement or Replacement?
- Serology Testing and Immunity: What’s next?
- Encountered Pre-analytical and Analytical issues: What to watch out for
- Role of Biochemical and Hematology testing in novel treatment monitoring
- Pediatric management of SARS-Cov2 viral infection or exposure and multisystem inflammatory syndrome in children
- Laboratory Management and Laboratory Safety
- Analytical and Clinical Validation Methods; Relationship between prevalence and test performance
- Therapeutic drug monitoring (e.g., anticoagulants, antiplatelet agents, etc) and drug interferences
- Point of care or Home testing
- Models for predicting positivity and severity

CONFERENCE ORGANIZING COMMITTEE

Khosrow Adeli, Canada (Chair)
Sergio Bernardini, Italy
Andrea Horvath, Australia
David Koch, USA
Giuseppe Lippi, Italy
Tomris Ozben, Turkey
Cheng-Bin Wang, China

Regional Federation Representatives:
- Rosa Sierra-Amor (Latin America)
- Ana-Maria Simundic (Europe)
- Ann Gronowski (North America)
- Rajiv Erasmus (Africa)
- Sunil Sethi (Asia-Pacific)
- Osama Najjar (Arab Federation)

Corporate Representatives:
- Rolf Hinzmann, Roche Diagnostics
- Patricia Ravalico, Abbott Diagnostics

Conference Organizing Secretariat
(MZ Congressi):
- Stefano Montalbetti

Regional Federation Representatives:
- Rosa Sierra-Amor (Latin America)
- Ana-Maria Simundic (Europe)
- Ann Gronowski (North America)
- Rajiv Erasmus (Africa)
- Sunil Sethi (Asia-Pacific)
- Osama Najjar (Arab Federation)

Corporate Representatives:
- Rolf Hinzmann, Roche Diagnostics
- Patricia Ravalico, Abbott Diagnostics

Conference Organizing Secretariat
(MZ Congressi):
- Stefano Montalbetti
ABSTRACTS

DEADLINE TO SUBMIT YOUR PAPERS: 5TH JANUARY 2021
(Abstracts are limited to 3250 characters, spaces included)

YOUNG INVESTIGATOR ORAL PRESENTATIONS
Call for submissions for COVID-19 related oral presentations.
Diverse and high ranking proposals will be selected
(can be data-driven or content-based)

VIRTUAL E-POSTER SESSION: for presentation by IFCC members and young scientists

Congress delegates are cordially invited to submit abstracts of their scientific work for presentation as a free communication at the IFCC Global Conference on COVID-19 in February 2021. An unlimited number of abstracts may be submitted provided the presenting author applies for “full registration”.
Abstracts are welcome in all fields of clinical chemistry, haematology, clinical molecular biology and laboratory medicine, in the broader sense. Free communications are primarily presented via poster. A limited number of abstracts will be selected for oral presentation during symposia. Authors wishing to compete for these oral communication slots should mark the appropriate field on the online abstract-submission form. Abstracts are limited to 3250 characters, spaces included

ABSTRACT TOPICS

• COVID-19: Innovations in In Vitro Diagnostics
• Molecular diagnosis of SARS-CoV-2 Infection
• Advances & challenges in viral antigen testing
• Advances in serological assays to monitor viral exposure
• Rapid testing and POCT diagnostics
• Antigen testing: Point of care and lab-based assays
• Analytical and clinical assay validation
• Serology testing and immunity
• Molecular testing and infectivity
• External quality assessment and assay standardization
• Orthogonal testing strategies
• Biochemical/hematological markers in patient monitoring
• Clinical risk scores and their global application
• Pediatric management of SARS-CoV-2 viral infection or exposure
• Multisystem inflammatory syndrome in children (MIS-C)
• Laboratory biosafety management
• COVID-19: Clinical/Public Health
• Preventive Medicine, Public Health and COVID-19

• COVID-19 Treatment & Future Perspectives:
• Emerging treatments and clinical practice paradigms
• Clinical value of Remdesivir
• Pharmacology and TDM
• Prognosis, pre/post exposure prophylaxis and antiviral treatment
• Convalescent plasma, selection of recipient and donor
• COVID-19 and Multisystem Organ Involvement
• Progression from respiratory infection to systemic disease
• Hematology and thrombotic complications
• Cardiovascular implications
• Gastrointestinal complications
• Dermatological manifestations
• Rheumatic diseases and COVID-19 susceptibility
• Pulmonary fibrosis and lung function
• Neurological associations
• Nephrology & the vasculature
• Pathological anatomy and cytology
• Key risk factors and role in pathophysiology
• Mental Health in the face of the COVID-19 pandemic

PLEASE CLICK HERE TO SUBMIT YOUR ABSTRACT
REGISTRATIONS

Online registrations available with the following fees

IFCC NATIONAL SOCIETY MEMBERS AND NON–MEMBERS € 100
CORPORATE/INDUSTRY REPRESENTATIVES € 100
YOUNG SCIENTISTS/TRAINEES (=/< 40 YEARS) FREE OF CHARGE

Registrations will include the possibility to:
- enter all sessions of the programme (both plenary and parallel)
- ask “live” questions and interact with the speakers
- visit industry virtual booths and attend educational workshops
- get the Certificate of Attendance
- enter the recorded sessions for 12 months after the conference date

VIRTUAL INDUSTRY EXHIBITS AND WORKSHOPS

Opportunities for both live and recorded exhibits and workshops by corporate members, IVD manufacturers and other member and non-member industry partners.
More information will be sent soon directly to companies’ representatives.